Pfizer On Lung Cancer: "We Need To Have Single-Agent Avelumab"

President-Pfizer Oncology Liz Barrett said the company remains committed to demonstrating the value of Bavencio in first-line lung cancer despite a recent setback that will push data out to 2019.